X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6222,709-   
Low Rs4582,353-   
Sales per share (Unadj.) Rs181.91,554.5-  
Earnings per share (Unadj.) Rs12.997.1-  
Cash flow per share (Unadj.) Rs29.3222.8-  
Dividends per share (Unadj.) Rs2.0085.01-  
Dividend yield (eoy) %0.43.4 11.0%  
Book value per share (Unadj.) Rs155.71,726.7-  
Shares outstanding (eoy) m804.51848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 182.4%   
Avg P/E ratio x42.026.1 161.0%  
P/CF ratio (eoy) x18.411.4 162.2%  
Price / Book Value ratio x3.51.5 236.7%  
Dividend payout %15.587.5 17.8%   
Avg Mkt Cap Rs m434,5162,146,042 20.2%   
No. of employees `00023.044.9 51.3%   
Total wages/salary Rs m26,3380-   
Avg. sales/employee Rs Th6,349.129,328.6 21.6%   
Avg. wages/employee Rs Th1,143.00-   
Avg. net profit/employee Rs Th449.31,832.1 24.5%   
INCOME DATA
Net Sales Rs m146,3021,318,175 11.1%  
Other income Rs m2,2870-   
Total revenues Rs m148,5891,318,175 11.3%   
Gross profit Rs m24,758360,983 6.9%  
Depreciation Rs m13,229106,549 12.4%   
Interest Rs m1,59425,891 6.2%   
Profit before tax Rs m12,222228,543 5.3%   
Minority Interest Rs m01,038 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-150,026 0.0%   
Tax Rs m1,798-2,790 -64.4%   
Profit after tax Rs m10,35482,345 12.6%  
Gross profit margin %16.927.4 61.8%  
Effective tax rate %14.7-1.2 -1,204.7%   
Net profit margin %7.16.2 113.3%  
BALANCE SHEET DATA
Current assets Rs m87,370890,291 9.8%   
Current liabilities Rs m33,081776,409 4.3%   
Net working cap to sales %37.18.6 429.5%  
Current ratio x2.61.1 230.3%  
Inventory Days Days8791 95.8%  
Debtors Days Days6296 65.0%  
Net fixed assets Rs m111,567430,545 25.9%   
Share capital Rs m1,6093,245 49.6%   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,2541,464,243 8.6%   
Long term debt Rs m36,454674,012 5.4%   
Total assets Rs m209,5323,012,453 7.0%  
Interest coverage x8.79.8 88.2%   
Debt to equity ratio x0.30.5 63.2%  
Sales to assets ratio x0.70.4 159.6%   
Return on assets %5.73.6 158.7%  
Return on equity %8.35.6 147.0%  
Return on capital %8.54.9 172.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,824210,049 11.3%  
From Investments Rs m-13,127-74,429 17.6%  
From Financial Activity Rs m-13,239-251,968 5.3%  
Net Cashflow Rs m-2,478-116,348 2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CIPLA With: VENUS REMEDIES  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  DR. DATSONS LABS  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS